ACT Genomics signs MOU with Bumrungrad International Hospital to offer services in Thailand

2018-07-06

ACT Genomics (ACTG) is pleased to announce that it has signed a memorandum of understanding (MOU) with Bumrungrad International Hospital (BIH) to offer genomic diagnostic services in BIH.

In recent years, genomic testing has gained increasing focus worldwide and also become an integral part of precision medicine.  By utilizing the cutting-edge next generation sequencing (NGS) platform to analyse the mutational landscape of patient’s tumour, coupled with ACTG’s proprietary bioinformatics pipeline and database, ACTG provides clinicians and cancer patients with personalized genomic information-based treatment options to guide their choice of therapy. This targeted approach aims to increase clinical outcomes, thereby reducing possible side effects and financial burden for patients.

"With this prestigious partnership in cancer diagnostics with BIH – a leading tertiary medical institution in the region with the most advanced technologies and expertise, we believe more cancer patients will be able to benefit from our award-winning genomic profiling services to improve their treatment outcomes," said ACTG Senior Vice President Dr. Allen Lai.

ACTG and BIH are excited about their partnership and aim to provide cancer patients with the best treatment options, by bringing precision medicine one step closer to them.


About ACT Genomics

ACTG is a cancer molecular information service company specializing in precision diagnosis and personalized treatments. Headquartered in Taipei, the company has offices in Singapore, Hong Kong, Tokyo and Shanghai, providing state-of-the-art cancer genomic profiling services to patients.  

The company has a clinical laboratory accredited by the College of American Pathologists. Its expertise include clinical sample preparation and sequencing, integrative genomics analysis and comprehensive clinical reports. In addition to its clinical services, ACTG also offers analytical solutions to clinical research institutes and biopharma.

For more information, please visit: http://www.actgenomics.com/


About Bumrungrad International Hospital

BIH is the Asia's first Joint Commission International accredited, multi-specialty hospital located in the heart of Bangkok, Thailand. Founded in 1980, it is one of the largest private hospitals in Southeast Asia, with 580 beds and over 30 specialty centres. BIH offers state-of-the-art diagnostic, therapeutic and intensive care facilities in a one-stop medical centre. The hospital serves 1.1 million patients annually, including over 520,000 international patients.

For more information, please visit: https://www.bumrungrad.com/en